Goldman Sachs Group Inc Cidara Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.48 - $13.08 $2,541 - $69,245	-5,294 Reduced 7.31%	67,097 $50,000
Q4 2022 Feb 13, 2023	SELL	$0.48 - $13.08 $2,541 - $69,245	-5,294 Reduced 7.31%	67,097 $50,000
Q3 2022 May 14, 2024	SELL	$0.45 - $13.0 $2,776 - $80,223	-6,171 Reduced 7.85%	72,391 $45,000
Q3 2022 Nov 10, 2022	SELL	$0.45 - $13.0 $2,776 - $80,223	-6,171 Reduced 7.85%	72,391 $0
Q2 2022 May 14, 2024	BUY	$0.43 - $0.91 $33,781 - $71,491	78,562 New	78,562 $38,000
Q2 2022 Aug 15, 2022	BUY	$0.43 - $0.91 $1,414 - $2,992	3,289 Added 4.37%	78,562 $38,000
Q1 2022 May 16, 2022	SELL	$0.67 - $1.39 $268 - $557	-401 Reduced 0.53%	75,273 $63,000
Q4 2021 Feb 14, 2022	SELL	$1.18 - $2.18 $40,379 - $74,599	-34,220 Reduced 31.14%	75,674 $96,000
Q3 2021 Nov 10, 2021	BUY	$1.48 - $2.35 $162,643 - $258,250	109,894 New	109,894 $246,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.63B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.